Ab­b­Vie set­tles one of its fi­nal Hu­mi­ra biosim­i­lar suits for an­oth­er mid-2023 de­layed en­try

Ab­b­Vie’s block­buster rheuma­toid arthri­tis drug Hu­mi­ra will see even more com­pe­ti­tion next year, as Ab­b­Vie and biosim­i­lar de­vel­op­er Alvotech set­tled a court dis­pute over when …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER